# Bridge Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bridge-biotherapeutics

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.bridgebiorx.com
- Total disclosed funding: $25M
- Latest round: Series B (Sep 29, 2017)
- Investors on record: 12

## About

Based in Seongnam-si, South Korea, Bridge Biotherapeutics, Inc. is an NRDO (No Research Development Only) biopharmaceuticals company that focuses on the development of new drugs and drug platforms for respiratory, inflammation, and oncology diseases. In 2015, Bridge Biotherapeutics, Inc. acquired an in-licensing agreement for BBT-401, a drug candidate for ulcerative colitis. In 2016, Bridge Biotherapeutics, Inc. established its subsidiary in the US. In 2019, Bridge Biotherapeutics, Inc. was listed on the KOSDAQ. The current CEO of the company is James Jungkue Lee. 

Bridge Biotherapeutics, Inc. develops several pipelines for respiratory, inflammation, and oncology diseases. Some of the main pipelines include BBT-877, autotaxin inhibitor, BBT-401, Pelino-1 inhibitor, and BBT-176, EGFR Tyrosine Kinase inhibitor. All of the three pipelines have passed pre-clinical study.

## Funding rounds

- Series B, Sep 29, 2017, $12M — SV Investment Partners, WOORI Venture Partners, IMM Investment, JB Investment, UTC Investment, KB Securities, LigaChem Biosciences Inc.
- Series A, Jul 30, 2016, $13M — SV Investment Partners, LB Investment, KB Investment, WOORI Venture Partners, HB Investment, Company K Partners, Lifecore Partners

## Investors

- SV Investment Partners (https://capitalatlas.ai/funds/sv-investment-partners) — Series A, Series B
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series A
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A, Series B
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series A
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A
- Lifecore Partners — Series A
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- JB Investment (https://capitalatlas.ai/funds/jb-investment) — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series B
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series B
- LigaChem Biosciences Inc. — Series B